Northwire Canada EditionThursday, September 3, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.2% OIL 91.30 +0.3% PALLADIUM 1436.00 +5.5% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9% LVG 0.305 −3.2% GAL 0.640 −4.5% WRX 0.040 +0.0% PHD 0.055 +22.2% DYG 0.135 +8.0% GR 0.075 +7.1% ANOR 0.080 +0.0% ADG 0.500 +0.0% MOON 8.41 +2.1% TRCG 0.180 +0.0% IMG 28.92 +3.5% GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.2% OIL 91.30 +0.3% PALLADIUM 1436.00 +5.5% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9% LVG 0.305 −3.2% GAL 0.640 −4.5% WRX 0.040 +0.0% PHD 0.055 +22.2% DYG 0.135 +8.0% GR 0.075 +7.1% ANOR 0.080 +0.0% ADG 0.500 +0.0% MOON 8.41 +2.1% TRCG 0.180 +0.0% IMG 28.92 +3.5%
Production / Operations Routine +

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

By The Northwire Desk — AI Analysis Apr 20, 2026 · 08:01 PHRM · 0.075 PharmaTher Holdings Ltd.
Executive Summary
  • The most recent release (April 20, 2026) positions PharmaTher's PatchPrint™ and PharmaPatch™ platforms to capitalize on U.S. regulatory shifts in psychedelics and peptides.
  • Key catalysts include a new Executive Order signed by President Trump to fast-track psychedelic research and potential FDA reclassification of therapeutic peptides (Category 1).
  • The company reports positive research results for psilocybin, LSD, DMT, MDMA patches and completed an IND-enabling study for its ketamine patch.
  • Peptide candidates identified include BPC-157, GHK-Cu, TB-500, and KPV, supported by provisional patent application No. 64/034,315 filed April 13, 2026.
  • The PatchPrint™ manufacturing platform is an automated tabletop microneedle patch 3D printer targeting compounding pharmacies and hospitals.
  • This follows a series of similar announcements in March and early April 2026 regarding the same peptide and psychedelic expansion strategies.
Material Impact
  • Rating Justification: The news reinforces existing strategic narratives established over the past three months (March-April 2026) rather than introducing new financial milestones or partnerships.
  • Regulatory Catalysts: While the Executive Order is a significant regulatory development, it aligns with previous FDA/HHS discussions mentioned in April 16 news; no immediate revenue impact is quantified.
  • Market Reaction Context: The stock price has declined significantly from $0.57 (August 2025) to $0.08 (April 2026), indicating market skepticism regarding the monetization of these regulatory tailwinds despite positive announcements.
  • Financial Reality: No new capital raised or specific partnership deal closed in this release; revenue drivers remain theoretical (licensing, system placements).
  • Conclusion: The information is positive but expected given the company's stated roadmap; it does not materially alter the risk profile or valuation immediately.
PHRM · Price
Company Overview
  • Company: PharmaTher Holdings Ltd., focused on microneedle patch technology and pharmaceutical manufacturing platforms.
  • Flagship Project: PharmaPatch™ (microneedle patch product platform) and PatchPrint™ (automated tabletop 3D printer for patches).
  • Key Programs: Ketamine (generic ANDA sold, proprietary LAI retained), Psychedelics (psilocybin, LSD, MDMA), Peptides (BPC-157, GLP-1), Parkinson's Disease (LID-PD Phase 3 ready).
  • Development Stage: Early-stage R&D for patches and peptides; late-stage planning for Parkinson's disease program.
  • Manufacturing: Proprietary automated dispensing and packaging system targeting compounding pharmacies and hospitals.
Read the original news release →

More from PharmaTher Holdings Ltd.

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other May 13, 2026 · 10:08

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

Other Apr 21, 2026 · 08:01

Strategic Alignment with Federal Psychedelic Mandate

Regulatory Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory Apr 13, 2026 · 08:01

PharmaTher Files Peptide Patch Patent as Stock Nears All-Time Lows Despite Pipeline Expansion

M&A / Property